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symptom). The Health Assessment Questionnaire (HAQ) was used to measure func-
tional status (scores 0–3). QoL was measured by the mental (MCS) and physical (PCS) 
component summary scores of the Short Form-8 (SF-8). Work/productivity loss was
measured by the Work Productivity and Activity Impairment (WPAI) instrument. 
Comparisons were made between patients who currently use SC biologics versus those 
who discontinued treatment. RESULTS: Of the 2,200 survey respondents (72%
female; average age  49.6years), 386 (17.5%) used SC biologics. The average dura-
tion of RA was 12.4 years, with 14% reporting severe disease. The patient-reported
mean scores were: morning stiffness 6.6, fatigue 6.8, pain 6.5, HAQ 1.6, MCS 43.9 
and PCS 36.4. Patients reported 61.0% work impairment and 59.2% impairments in 
daily activity. Patients who had discontinued SC biologic therapy (N  124, 32.1%)
reported signiﬁ cantly worse scores in morning stiffness, fatigue, pain, and PCS (all
P  0.05) versus patients currently treated with SC biologics (N  262, 67.9%). 
Patients who discontinued therapy had more work/activity loss; only activity impair-
ment was statistically signiﬁ cant (P  0.05). There was no signiﬁ cant difference in
HAQ scores between groups. CONCLUSIONS: RA patients using current SC biolog-
ics still suffer from serious impairments in symptoms, functional status, QoL, and 
work/productivity. However, patients who discontinued SC biologic therapy have sig-
niﬁ cantly worse symptom scores, physical functioning, and activity impairment com-
pared with those currently being treated. Both ﬁ ndings indicate there is still an unmet
medical need in RA patients.
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OBJECTIVES: To estimate changes in quality of life (SF36) and utility (SF6) in 
patients treated with naproxcinod, naproxen or placebo for 13 weeks, and to explore
the effect of different disease measures on utility. METHODS: SF36 was available
from 3 international ph 3 clinical trials in 2738 patients with knee or hip osteoarthritis 
comparing 2 doses of naproxcinod (375 and 750 mg bid) to naproxen (500 mg bid) 
and placebo. Efﬁ cacy was based on the pain, function and composite scales of the 
WOMAC™ osteoarthritis index. Co-morbidity measures included hypertension (HT)
which increases with NSAID therapy, body mass index (BMI) and diabetes. Changes
in SF6 and individual SF36 domains were compared between the groups using 
ANOVA and Dunett’s 2-sided test. The effect of the WOMAC™ indices, BP, BMI and 
diabetes on utility scores was explored using multiple regression analysis. RESULTS:
All SF36 subscales except mental health as well as utility changed signiﬁ cantly from 
baseline for all groups, and were correlated with changes in the WOMAC™ indices 
(p  0.001). The change in the active groups was signiﬁ cantly better than placebo for
pain and physical function (0.05), but not signiﬁ cantly different between treatments.
However, absolute changes in utility, pain, physical function and general health were
generally larger for naproxcinod 750 mg than naproxen 500 mg by around 10%.
Utility scores correlated signiﬁ cantly with WOMAC™, and patients with high BMI
and BP or diabetes had lower utility scores and worse WOMAC™ indices. Increase 
in utilities were larger for patients with 750 mg naproxcinod than for the other groups. 
CONCLUSIONS: The slightly larger utility and quality of life changes with naprox-
cinod 750 mg despite a similar effect as naproxen on WOMAC™ may be explained 
by a different side-effect proﬁ le and a neutral blood pressure effect.
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OBJECTIVES: To utilize WebTV technology as a tool to measure HRQOL in elderly
persons having Rheumatoid Arthritis (RA) in a nationally representative sample and 
to describe their socio-demographic characteristics, medication use and other treat-
ment choices. METHODS: A cross- sectional online survey research design. Random
digit dialing (RDD) survey procedures were used to draw a sample of 550 elderly 
arthritic individuals from US households across 44 states. A subsample of 79 individu-
als previously diagnosed with RA completed SF-36v2 survey, as part of a larger study.
Eight SF-36 domain scores and Physical and Mental Component Summary (PCS and
MCS) scores were computed and compared with cross-sectional norms for general US
population. RESULTS: Compared to the general population, our study sample per-
formed poorly with respect to all the SF-36 domains except mental health (MH) and 
social functioning (SF) domains. RA is more prevalent in whites (96%) and males 
reported higher scores for all the eight SF-36 domains than females. About 92% of 
the sample reported the use of at least one available OTC arthritic medication; 58% 
of the sample was taking prescription drugs, while about 53% reported having used
natural/herbal remedies for arthritis. A signiﬁ cant difference (p  0.003) was found 
between males and females with respect to only PCS scores. Age was found to correlate 
negatively (p  0.005) with PCS and MCS summary measures, particularly for indi-
viduals 70 years and older. CONCLUSIONS: WebTV is an effective survey administra-
tion tool for measuring HRQOL. As expected, elderly perform poorly on three of the
SF-36 domains (PF, RP, BP) having the most physical factor content. Prescription drug
use is fairly prevalent and use of OTC medications and other forms of treatment is 
popular in the population under study.
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OBJECTIVES: Through data analysis we will examine and identify the lifestyle factors 
that impact clinical outcomes of Rheumatoid Arthritis (RA) patients. METHODS:
Patients’ self-reported data was collected from the 2008 RA Patient Survey, an Internet 
survey of RA patients. We studied the effects of aerobic exercise (20 minutes a day 
per month), and cigarette smoking on RA patients. Sign and symptom scores for 
morning stiffness, fatigue, and pain are deﬁ ned from 0 (no symptom) to 10 (severe
symptom) within the survey. The Health Assessment Questionnaire (HAQ) was used
to measure functional status scores (0–3). Quality of life was measured by the mental 
component score (MCS) and physical component score (PCS) of the Short-Form 36
(SF-36). Productivity was measured by the Work Productivity and Activity Impairment 
(WPAI) Scale. There were no non-RA controls included in the study. RESULTS: A
total of 2048 respondents were included in the analysis 1001 patients exercised and
584 patients smoked cigarettes. The average age was 51.9 years and average RA 
duration was 11.9 years. Patients’ mean MCS and PCS scores in the exercise (40.7, 
36.7) and non-smoking groups (41.2, 34.4) were signiﬁ cantly higher, than in the non-
exercise (40.0, 31.3) and smoking groups (37.4, 32.7). Overall work and productivity
impairment was 41.5% (exercise) versus 45.4% (non-exercise), and 45.5% (smoking)
versus 42.2% (non-smoking). Signs, symptoms, and HAQ scores were signiﬁ cantly 
better in the exercise and non-smoking groups (all P  0.05). CONCLUSIONS: RA
patients who exercise regularly have higher quality of life scores and clinical outcomes. 
Those that smoke cigarettes have lower quality of life scores and higher symptom/
HAQ scores suggesting that this habit may be detrimental to their clinical outcomes.
These results suggest that these lifestyle choices inﬂ uence the overall risk of impairment 
in RA patients.
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OBJECTIVES: QALYs are an important outcome used in cost-effectiveness analysis. 
The Health Utilities Index Mark 3 (HUI-3) is a self-reported measure covering 8 attri-
butes of health status. Our objective was to assess construct validity and responsiveness 
of HUI-3 in ankylosing spondylitis (AS). METHODS: Data were derived from the 
Adalimumab Trial Evaluating Long-Term Efﬁ cacy and Safety in AS (ATLAS). We speci-
ﬁ ed a priori hypotheses regarding the direction and magnitude of associations expected
between overall and single-attribute HUI-3 scores and other health status and quality
of life measures—SF-36, ASQOL, Bath AS Functional Index (BASFI), Bath AS Disease
Activity Index (BASDAI), and Patient’s Global Assessment (PGA). Using baseline data,
we calculated correlation coefﬁ cients and interpreted them via guidelines suggested by 
Guyatt for negligible, weak, moderate, and strong associations. Responsiveness was 
assessed by calculating standardized response means (SRMs) of HUI-3 scores from
baseline to Week 24 for patients meeting the minimum clinically important differences
(MCID) for the ASQOL (1.8). Responsiveness analysis was limited to patients with 
24-week HUI-3 scores. RESULTS: A total of 295 of the 315 patients enrolled in ATLAS 
were included in the analysis. Mean age was 43 years, 76.3% were male, and mean 
duration of AS was 11 years. Correlation coefﬁ cients between HUI-3 scores and other 
instruments conﬁ rmed 62.2% of the a priori hypothesis, with an additional 24.5% 
being under- or over-estimated by only one category. Results of responsiveness analysis 
demonstrated that there were signiﬁ cant differences in overall HUI-3 (SRM 1.13) and
most single-attribute change scores for patients whose changes were greater than the 
ASQOL MCID vs. those whose changes were MCID. CONCLUSIONS: These results 
suggest that HUI-3 constructs are related to similar constructs in other measures, as
expected. This study provides evidence of cross-sectional and longitudinal construct 
validity of the HUI-3 for deriving utility scores for AS patients.
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OBJECTIVES: We aimed to validate the multi-attribute health utility (MAHU) derived 
from the CAT-5D-QOL, a computer-adaptive instrument composed of 5 domains 
(Walking, Handling Objects, Daily Activities, Pain/Discomfort, and Feelings) in people 
with self-reported osteoarthritis (OA), and to compare it with WOMAC_HUI3, the 
utility derived from the standard disease-speciﬁ c measure in OA. METHODS: Data 
were collected from participants (age 50) who completed questionnaires CAT-5D-
QOL in two waves and WOMAC in one wave of a Canada-wide online survey. To 
assess construct validity, we used multivariable regression to examine the associations
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between utilities and self-rated general health (GH, on a 5-point Likert scale), presence 
of several co-morbid conditions, and use of drugs. We assessed the responsiveness of 
CAT-5D-QOL by comparing changes in MAHU scores with changes in GH (anchor 
variable) between the two waves of the survey. RESULTS: There was a strong correla-
tion (Pearson r  0.77, n  520) between MAHU and WOMAC_HUI3 but the mean 
MAHU was signiﬁ cantly lower (0.79 vs. 0.86). No ceiling or ﬂ oor effect was observed
for either utility. Compared to WOMAC_HUI3, regression analysis demonstrated
generally stronger association for MAHU with the number of analgesic drugs taken 
and self-reported GH scores. MAHU also showed signiﬁ cant associations with the
presence of back pain, depression, ulcer, and cancer, whereas WOMAC_HUI3 corre-
lated only with back pain. In the analysis of responsiveness, differences in mean
MAHU scores were in the expected direction and signiﬁ cantly different for each level
of change in GH scores. CONCLUSIONS: MAHU and WOMAC_HUI3 were highly
correlated and neither measure had a ceiling or ﬂ oor effect. However, MAHU dem-
onstrated better discriminative ability with respect to several health-related variables.
MAHU was also sensitive to changes in overall health over time. These are all desirable 
properties for capturing the health impact of OA (and other conditions) and estimating 
cost-effectiveness of health interventions.
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OBJECTIVES: To validate the Oxford Knee Score (OKS) in outpatients with knee 
osteoarthritis (OA) in Shanghai. METHODS: Eligible patients were interviewed using 
a pretested questionnaire containing the OKS, the SF-6D, and the EQ-5D. Reliability
was assessed using Cronbach’s alpha, dimensionality using principal component factor
analysis and item-total correlations, convergent and discriminant construct validity 
using expected correlations between the OKS and the SF-6D and the EQ-5D. 
RESULTS: The Chinese OKS was well accepted by patients in a pilot testing. When 
administered to a convenient sample of 187 patients with knee OA (mean age 64 
years, 74% female, mean duration of OA 7.6 years), Cronbach’s alpha exceeded 0.8
and factor analysis yielded 2 factors with eigenvalue 1. Hypothesized item-total cor-
relations (¦Ñ q 0.4) were observed for all items. Convergent construct validity was 
supported by the presence of hypothesized moderate to strong correlations between
the OKS and SF-6D physical functioning, role limitation, social functioning, and pain,
EQ-5D mobility, self-care, usual activities, and pain/discomfort, and mobility VAS (¦Ñ 
 0.47 to 0.82). Discriminant construct validity was not satisfactory. The OKS corre-
lated weakly with SF-6D vitality (¦Ñ  0.35), but strongly with SF-6D mental health
and EQ-5D anxiety/depression (¦Ñ  0.51 and 0.41, respectively). CONCLUSIONS:
The OKS has demonstrated good psychometric properties and thus can be regarded
as a reliable and valid measurement in outpatients with OA.
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OBJECTIVES: Previous studies have suggested that adults with arthritis are less physi-
cally active than adults without arthritis. However, these studies were mostly based
on crude prevalence comparisons and general physical activity recommendations. Our 
objectives were: 1) to examine the physical activity proﬁ le of adults with arthritis; 2)
to compare physical activity in adults with arthritis with arthritis-speciﬁ c activity rec-
ommendations; and 3) to identify key determinants of participation in physical activ-
ity. METHODS: Using Statistics Canada’s 2005 Canadian Community Health Survey
(CCHS, n  132,221), we determined frequency of participation in different types of 
activity and calculated amount (minutes/day) of daily physical activity for adults with
self-reported, physician-diagnosed arthritis. Subjects met arthritis-speciﬁ c physical 
activity recommendations if they fulﬁ lled three criteria based on American College of 
Rheumatology guidelines: 1) total activity 15 minutes/day and participation in 2) 
aerobic exercise and 3) ﬂ exibility/strengthening exercise. Multiple logistic regression 
models were used to identify sociodemographic and health factors associated with
meeting physical activity recommendations. RESULTS: There were 23,503 subjects 
with reported physician-diagnosed arthritis (prevalence, 15.1%) in the CCHS. Of 
these, 61% performed 15 minutes/day of activity; the most frequently reported 
aerobic and ﬂ exibility/strengthening exercises were walking (65.7%) and home exer-
cise (30.5%), respectively. Overall, 26% of subjects met arthritis-speciﬁ c physical
activity recommendations. Factors that were associated with meeting recommenda-
tions included being female (adjusted OR 1.16 [1.08–1.23]) and having post-second-
ary education (1.93 [1.78–2.09]). Negatively associated factors included smoking 
(0.62 [0.57–0.68]), and overweight (0.80 [0.74–0.86]) and obese status (0.58 [0.54–
0.63]). CONCLUSIONS: We found that 26% of adults with arthritis met speciﬁ c
activity recommendations. Examination of speciﬁ c activities identiﬁ ed walking as an
important contributor to aerobic and total activity in people with arthritis. In addition, 
evaluation of correlates of physical activity identiﬁ ed males, overweight or obese 
individuals and those with lower education levels as target groups for potential inter-
vention strategies.
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OBJECTIVES: To evaluate the impact of golimumab (GLM) on productivity in anky-
losing spondylitis (AS) patients. METHODS: GLM was studied in a multicenter, ran-
domized, placebo (PBO)-controlled study (GO-RAISE) in which 356 patients were 
randomized (1.8:1.8:1 ratio) to receive subcutaneous GLM 50 mg, 100 mg, or PBO
q4 wks. Patients with Ankylosing Spondylitis (AS) (BASDAI and back pain score each 
q4) were eligible. Productivity was measured on a VAS scale (0–10 cm). Change in
productivity from baseline to wk16 and wk24 was compared between groups. At 
wk16, patients who received PBO or GLM 50 mg and had 20% improvement in 
total back pain and morning stiffness entered early escape in a double-blind fashion.
All other patients remained on their previous medication until wk24. The last observa-
tion for patients who entered early escape prior to change in treatment was carried 
forward in the wk24 analyses. Observed values at wk24 were used for GLM 100 mg 
patients. An ANOVA on van der Waerden normal scores was performed for between-
group differences. RESULTS: Patients in the GLM 50 mg, 100 mg, and PBO groups 
had similar mean o SD baseline scores of 6.6 o 2.5, 6.8 o 2.3, and 6.3 o 2.5, respec-
tively. Mean improvement in self-reported productivity was signiﬁ cantly greater with 
the GLM 50 mg group than the PBO group at wk16 (2.8 o 3.0 vs. 0.4 o 2.7; p 
0.001) and wk24 (2.7 o 3.1 vs. 0.5 o 3.0; p  0.001). Signiﬁ cantly greater improve-
ment was observed with the GLM 100 mg group than the PBO group at wk16 (2.9 
o 2.9 vs 0.4 o 2.7; p  0.001) and wk24 (2.9 o 3.0 vs. 0.5 o 3.0; p  0.001). 
Change from baseline in productivity was similar in both GLM dose groups at wk16 
and wk24. CONCLUSIONS: AS patients treated with GLM 50 mg and 100 mg had 
signiﬁ cant improvement in self-reported productivity, with improvement at wk16 
maintained through wk24.
PMS48
GOLIMUMAB, A HUMAN ANTI-TNF-ALPHA MONOCLONAL
ANTIBODY, SIGNIFICANTLY IMPROVES SELF-REPORTED
PRODUCTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS: 
RESULTS FROM THREE PHASE 3 STUDIES
Buchanan J1, Fleischmann R2, Genovese MC3, Kay J4, Hsia EC5, Doyle MK5, Rahman MU5, 
Han C1, Parasuraman S1
1Johnson & Johnson Pharmaceutical Services LLC, Malvern, PA, USA, 2Univeristy of Texas
Southwestern Medical Center, Dallas, TX, USA, 3Stanford University, Palo Alto, CA, USA, 
4Massachussetts General Hospital/ Harvard Medical School, Boston, MA, USA, 5Centocor 
Research and Development, Inc./ U Penn Medical School, Malvern/ Philadelphia, PA, USA
OBJECTIVES: To evaluate the effect of golimumab (GLM) on self-reported productiv-
ity in rheumatoid arthritis (RA) patients. METHODS: The effect of GLM on self-
reported productivity was evaluated in three multicenter, randomized, double-blind, 
placebo (PBO)-controlled studies in RA patients. The trials evaluated different 
patient populations and included patients naïve to MTX (GO-BEFORE), patients with
active RA despite MTX (GO-FORWARD), and patients previously treated with anti-
TNF-alpha agent(s) (GO-AFTER). GLM subcutaneous injections of 50 mg or 100 mg 
were administered q4ks. At wks0 and 24, patients rated their productivity on a VAS
scale (0–10 cm) at work, school or at home after 4wks. A negative mean change from 
baseline is an improvement in self-reported productivity. An ANOVA on van der
Waerden normal scores was performed for between-group comparisons. RESULTS:
Mean baseline scores for self-reported productivity were comparable between groups
(ranges were 6.3–6.4[GO-BEFORE]; 5.4–5.7[GO-FORWARD], 6.2–6.7[GO-AFTER]). 
In GO-FORWARD, the mean(SD) improvements in self-reported productivity were 
signiﬁ cantly greater in the GLM 50 and 100 mg  MTX groups compared with PBO 
 MTX at wk24 (1.97 o 3.12, 2.00 o 2.53, and 0.45 o 2.98, respectively, p 
0.001). In GO-AFTER, the mean(SD) improvements in self-reported productivity 
were signiﬁ cantly greater in the GLM 50 and 100 mg groups compared with PBO at 
wk24 (1.77 o 2.90, 2.10 o 2.92, and 0.52 o 2.79, respectively, p  0.001). In 
GO-BEFORE, numerical improvements in self-reported productivity were observed in
the GLM 50 and 100 mg MTX groups (2.48 o 2.94 and 2.90 o 2.80, respectively); 
these improvements were not signiﬁ cantly different from PBO  MTX (2.27 o 3.02). 
CONCLUSIONS: In two studies, GLM resulted in signiﬁ cant improvements in self-
reported productivity. In the third trial, GLM resulted in trends towards improvement
in self-reported productivity compared with PBOMTX.
